Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
Open Access
- 30 April 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (4), 650-657
- https://doi.org/10.1038/mt.2010.312
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Targeting Localized Immune Suppression Within the Tumor Through Repeat Cycles of Immune Cell-oncolytic Virus Combination TherapyMolecular Therapy, 2010
- Independent Regulation of Chemokine Responsiveness and Cytolytic Function versus CD8+ T Cell Expansion by Dendritic CellsPublished by The American Association of Immunologists ,2009
- Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccinesCancer Immunology, Immunotherapy, 2009
- Chemical control of protein stability and function in living miceNature Medicine, 2008
- Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemiaJournal of Leukocyte Biology, 2008
- Structure and Function of A41, a Vaccinia Virus Chemokine Binding ProteinPLoS Pathogens, 2008
- Adoptive Cell Transfer TherapySeminars in Oncology, 2007
- Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia VirusPLoS Medicine, 2007
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963JCI Insight, 2007
- CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistenceThe Journal of Experimental Medicine, 2006